Skin, Hair & Beauty

The Body's Own Repair Signal — And the Evidence Gap Between What It Does and How People Use It

Discovered by Immunologists, Repurposed by Horse Trainers, and Now It May Be a Prodrug

Alpha-MSH's Anti-Inflammatory Fragment — And It May Work Completely Differently Than Everyone Thinks

NOT a Peptide — A Synthetic Heterocyclic Amine. Zero Human Clinical Trials. The Most Compelling In Vitro Dopaminergic Neuroprotective Profile in the Nootropic Space. Also a MAO-A Inhibitor (IC50 = 1 μM) With Tyramine Reaction and Serotonin Syndrome Risk. Also a Photosensitizer With UV-Activated DNA Damage Potential. The Most Dangerous Safety Profile of Any Nootropic in This Book.

Engineered to Not Be EPO. Proven to Regenerate Nerves in Humans. WADA Banned Anyway. And the Company That Made It No Longer Exists.

NOT a Peptide — An Oral Small Molecule Drug in Active Phase 1b/2 Clinical Development. Formerly O-304 (Betagenon). Now ATX-304 (Amplifier Therapeutics / Cambrian Bio). Pan-AMPK Activator + Mitochondrial Uncoupler. Exercise Mimetic. Phase 2a Human Data: Significant Fasting Glucose Reduction in T2D. Multiple Strong Animal Studies: Fat Loss, MASLD, Cardiovascular, Kidney Protection. The Most Clinically Advanced Novel Compound in This Book.

GlaxoSmithKline Halted Their Own Drug in 2007 Because It Caused Cancer in Every Animal Species They Tested. The Community Is Still Using It. The Drug Worked. That Is the Entire Problem.

The Most Prescribed GH Secretagogue Combination in Clinical Practice — and the One Decision That Changes Everything: DAC or No DAC.

The Only Senolytic With Real Human Trial Data. Tested at the Mayo Clinic. Proven to Clear Senescent Cells in Humans. Dasatinib Is a Chemotherapy Drug. The Community Is Using It Without Prescriptions, ECGs, or Drug Interaction Screens.

Reported to Be 10 Million Times More Potent Than BDNF. The Foundational Mechanistic Data Is Under a Research Integrity Cloud. The Clinical Prodrug Failed Phase 2/3. The Community Uses It Anyway.

The Pure Active Isomer in Clomid. The Drug That Raised Testosterone as Well as TRT While Preserving Fertility — and Still Failed FDA Approval. The Zuclomiphene Problem: Why the Racemic Mixture Causes Side Effects Pure Enclomiphene Shouldn't. The NDA That Died in 2021. How It Differs from TRT, HCG, and Gonadorelin for Male Hypogonadism. The 2025 Meta-Analysis: +273 ng/dL Testosterone vs Placebo.

The World's Best-Selling Senolytic Supplement. One Landmark Mouse Study. One ITP Failure. Multiple Human Trials Running for Years With No Published Senolytic Endpoint Data. The Bioavailability Problem Nobody in the Marketing Ecosystem Discusses.

A 2017 Paper Showed It Extended Mouse Lifespan by 24.8%. The Community Is Already Injecting It. There Has Never Been a Human Safety Trial. And It Works by Interfering With p53.

NOTE: This chapter covers GHK as a free tripeptide — its endogenous biology, copper-carrier function, and primary topical cosmetic applications. The systemic, injectable, and regenerative applications of the copper-chelated complex are covered in the GHK-Cu chapter, which should be read alongside or before this chapter. Plasma Levels: 200 ng/mL at Age 20, Declining to 80 ng/mL by Age 60. The Connectivity Map and 4,000 Genes. Loren Pickart (1938–2023). The Copper Switch.

Zero Published Human RCTs for the Injectable Route. Every Protocol is Extrapolated from Topical and Animal Data. The Anela Protocol: The Community Standard Defined. ISR Management: Why 3mL/50mg is the Standard Dilution. Copper Accumulation Risk on Long Cycles. The Systemic Healing Signal: Animal Evidence That Injected GHK-Cu Heals at Remote Sites. The Active Malignancy Hard Stop. Reconstitution Guide. Stacking with BPC-157 and TB-500 in the GLOW Protocol.

8+ Human RCTs on Topical Application. The Compound That Outperformed Vitamin C and Retinoic Acid for Collagen Deposition. Leyden 2002: 67% Reduction in Wrinkle Volume at 12 Weeks. Yuvan 2023: +28% Skin Collagen Density by Dermal Ultrasound. The Active Malignancy Contraindication Applies Regardless of Route. The Route Gap That Makes This Chapter Necessary: Topical Evidence Is Not Evidence for Injectable. See GHK-Cu (Injectable) for the Zero-RCT Community Protocol.

The Compound Every Secretagogue in This Book Targets. 191 Amino Acids. FDA-Approved for GH Deficiency, HIV Wasting, Short Bowel Syndrome. July 2025: Skytrofa Once-Weekly Now Approved for Adults. The Pulsatile vs Continuous GH Exposure Distinction. IGF-1 as the Surrogate Marker. The Fake HGH Crisis. WADA S2 Absolute Ban. Why Secretagogues (Sermorelin, Ipamorelin, MK-677) Are Different. The Active Malignancy Hard Stop. The Cancer-IGF-1 Question That Never Goes Away.

Four Organ-Specific Bioregulators from the Russian Khavinson Research Tradition. The Theory That Short Peptides Regulate Gene Expression in a Tissue-Specific Way. Cortexin: A Russian-Approved Neuroprotective Extract with Multi-Receptor Activity. CardioCytogen (Ala-Glu-Asp-Arg): The Cardiac Fibroblast Modulator. Crystagen: Connective Tissue and Cartilage Bioregulator. Bronchogen: Pulmonary Bioregulator Tetrapeptide. The Shared Evidence Architecture That Applies to All Four.

Every Cell Makes It. Every Major Disease Depletes It. Oral Supplementation Below 1% Bioavailability in Standard Form. IV Delivery With Documented Fatalities. A Billion-Dollar Skin Whitening Industry Built on Mixed Evidence. The Precursor Strategy That Outperforms the Molecule Itself.

⚠ NAMING COLLISION: 'Lipo-C' is used for TWO completely different products — this chapter covers the compounded MIC+L-Carnitine+B-vitamins lipotropic injection. Liposomal Vitamin C (a separate oral supplement also called 'Lipo-C') is covered in a separate chapter. Read Section 1 before proceeding. Lipo-B Extended: Adds L-Carnitine, Thiamine (B1), and Dexpanthenol (B5) to the Lipo-B MIC+B12 base. Zero RCTs for the combination. L-Carnitine Injectable Dose is 100-200x Below Oral Therapeutic Doses. Mechanistically Coherent. Clinically Unproven.

The Only Human Cathelicidin. Antimicrobial, Anti-Biofilm, Pro-Angiogenic, Immunomodulatory, Wound-Healing. Phase IIb Clinical Evidence in Chronic Wounds. Overexpressed in Rosacea, Ovarian Cancer, Breast Cancer, Lung Cancer, Melanoma. Tumor-Suppressive in Colon and Gastric Cancer. The Most Contextually Bidirectional Compound in This Book. Vitamin D Is Its Most Important Natural Inducer.

FDA-Approved. EMA-Approved. The First Effective Treatment for a Disease That Traps Patients Indoors. The Compound That Tans Without UV. The Nevi Darkening Warning the Community Ignores. The Melanoma Question That Has No Clean Answer. The Widest Gap in This Book Between the Disease It Was Made For and the Use It Is Actually Known For.

One Molecule That Tans Your Skin, Triggers Erections, Suppresses Appetite, and Elevates Blood Pressure — All Through Different Receptors on the Same Injection. The University of Arizona Drug That Spawned PT-141. Why the 'Barbie Drug' TikTok Trend Is the Most Dangerous Community Use Pattern in This Book. The Melanoma Question: Four Case Reports, Two Conflicting Reviews, and One Confound. Rhabdomyolysis at 12x the Starting Dose. What the Nasal Spray Market Actually Contains.

Tuftsin → Selank → N-Acetyl Selank Amidate: Three Generations of Molecular Engineering. Russian-Approved Anxiolytic Without Sedation, Without Tolerance, Without Dependence. Comparable to Benzodiazepines for GAD With Psychostimulant Properties They Lack. BDNF Upregulation. Enkephalin Stabilization. The Evidence Is for Selank. NASA Is the More Stable Delivery Format Whose Equivalent Efficacy Is Chemically Logical but Clinically Unproven.

This addendum expands the NAD+ chapter with a dedicated section on subcutaneous injectable NAD+ — covering pharmacokinetics, why SubQ differs from oral precursors and IV infusion, reconstitution from lyophilised vials, injection technique, dose titration, side effect management, and the honest evidence comparison with oral NMN/NR and IV administration.

The Most Legitimate Longevity Target in This Book. The Most Commercially Weaponized. The Man Promoting NMN Has Financial Ties to NMN. The Man Criticizing Him Has Financial Ties to NR. The Clinical Evidence Is Real and More Modest Than Either Side Tells You.

FDA-Approved at 50 mg for Opioid and Alcohol Use Disorder Since 1984. Off-Label at 1.5-4.5 mg (LDN) — Two Completely Different Mechanisms at Two Completely Different Doses. TLR4 Blockade on Microglia. The Endorphin Rebound. A Lancet Rheumatology RCT in 2024. An Evidence Base Growing Faster Than Pharma Has Any Reason to Fund. The Most Favorably Tolerated Prescription Drug in Its Evidence Literature.

The Most Clinically Studied SARM. The Phase 3 Trials That Nearly Got It Approved. Why the FDA Said No — and Why It Matters. The Most Modest HPTA Suppression Profile in the SARM Class. The Lowest Hepatotoxicity Signal. The Closest Any SARM Has Come to an FDA Indication. Why Phase 3 Failure Doesn't Mean the Compound Doesn't Work. Jonas Brodin and the NHL Doping Case.

The First Peptide Ever Synthesized (Nobel Prize 1955). FDA-Approved for Obstetric Use Since the 1950s. The 'Love Hormone' That Science Has Substantially Complicated. Intranasal Bioavailability ~2%. Trust Enhancement Replication Failures. Autism Trials: Mixed to Null. Context-Dependent Effects That Can Go Either Direction. And an OTC Nasal Spray Industry Built on Evidence That Doesn't Support What It Claims.

The Only FDA-Approved Peptide in This Book — Approved for Women, Used Primarily by Men, for Different Reasons, With Different Evidence.

The Selectivity Claim That Doesn't Hold Up in the Only Published Human Trial. Phase 1 Breast Cancer Study: 59% Elevated AST, 45% Elevated ALT. Six or More Published DILI Case Reports — Including Near-Transplant Cholestatic Hepatitis. HPTA Suppression: As Real as Testosterone. WADA S1.2 Absolute Ban. FDA Warnings. The 53% Problem: Only Half of SARM Products Contain What They Claim. Why 'Fewer Side Effects Than Steroids' Doesn't Mean Safe.

The ITP Mouse Data: Lifespan Extended at Multiple Labs, Doses, and Start Ages. The PEARL Trial (April 2025): First 48-Week Placebo-Controlled Human Longevity Trial Published. The Bioavailability Finding That Changes Everything: Compounded Rapamycin Is ~3x Less Bioavailable Than Commercial. Intermittent vs Continuous Dosing: The Pharmacological Divide Between Transplant Medicine and Longevity Use. The Immunosuppression Risk That Needs Honest Framing. The Drug Interaction Profile That Makes This the Most Dangerous Compound in This Book to Stack. Why the Community Uses ~6 mg Weekly. What Happens When You Stop.

28.7% Weight Loss in Phase 3. The Most Effective Weight Loss Drug Ever Trialed. Not Approved. Not Available by Prescription. The Community Is Already Using It. And It Is Not the Same Drug as Tirzepatide.

Russia Approved It. The West Has Never Independently Validated It. And It Might Be the Only Anxiolytic That Doesn't Make You Stupid.

Genuinely FDA-Approved for 18 Years. Withdrawn for Commercial Reasons, Not Safety. The Gateway Anti-Aging Peptide for a Decade of Compounding Medicine. Put on Category 2 in 2023. Apparently Returned to Category 1 Before the Broader 2026 Reclassification. The Cleanest Safety Profile of Any GH Secretagogue. The Somatostatin Feedback Ceiling That Makes It Physiologically Impossible to Overdose.

The Compound Designed for Patients Whose Brains Literally Cannot Signal 'Stop Eating.' The POMC/LEPR/PCSK1 Pathway Explained: Why These Patients Gain Weight from the Day They Are Born. 80% Achieved ≥10% Weight Loss in the POMC Trial. 51 kg Lost in a Single Patient in Phase II. The Off-Label Question: Does It Work When the Pathway Is Intact? Why 78% of Patients Develop Skin Hyperpigmentation — and Why That Is Not the Same Risk as Melanotan II. vs MT-II: Same Receptor Family, Opposite Selectivity Approach.

Topical Cosmeceutical ONLY — NOT Injectable. Argireline Extended by Two Amino Acids. Targets the Same SNARE Complex as Botulinum Toxin — Via a Completely Different and Far Weaker Mechanism. The Penetration Problem: <0.2% of Applied Peptide Crosses the Stratum Corneum Passively. The 63% Claim: Manufacturer-Sponsored, 17 Subjects, Not Independently Replicated. Microneedle Delivery Genuinely Improves Outcomes. Dynamic Wrinkles Only.

GLOW Stack is the Wolverine Stack with GHK-Cu added

is not evidence quality — it is scope appropriateness

KLOW is mechanistically the most comprehensive tissue repair protocol in this book — four non-overlapping mechanisms covering angiogenesis, cell migration, ECM remodeling, and inflammatory suppression simultaneously. The tension: comprehensiveness is not the same as superiority. Adding a fourth compound means: more injections (or more complex blended vial formulation); more copper accumulation risk on extended cycles (GHK-Cu); more cost; and more moving parts when something doesn't work as expected. For many users, GLOW already covers their needs; KLOW is the right choice when the inflammatory dimension or gut protection is a specific priority. The chapter exists to clarify when KLOW is worth the additional complexity.

Most Widely Used Peptide Healing Combination in Community History

The TB-4 Fragment That Has Nothing to Do With Actin. Why ACE Inhibitors Raise Ac-SDKP Levels — and Why That Might Explain Some of Their Anti-Fibrotic Effects. Cardiac and Renal Fibrosis Prevention in Animal Models. Produced in the Body by Prolyl Oligopeptidase Cleaving Thymosin Beta-4. The Fragment With More Published Independent Research Than Its Parent Compound. No Human RCT for Community Use.

The Most Referenced Compound in This Book Given Its Own Chapter. FDA-Approved for Confirmed Hypogonadism. Schedule III Controlled Substance. WADA S1 Absolute Ban. TRAVERSE Trial (NEJM 2023): TRT Does Not Increase Cardiovascular Events in Hypogonadal Men. The TTrials: Sexual Function, Bone Density, Anemia All Improved. The Central Paradox: The Compound That Is Appropriate Medical Treatment at One Baseline Testosterone Level Is Misuse at Another. Aromatization, Estradiol Management, HPTA Suppression, Testicular Atrophy, Fertility, and the Full Monitoring Protocol.

The Only Thymic Hormone That Requires a Metal Cofactor. Biologically Inactive Without Zinc. The Most Important Clinical Point: Zinc Deficiency Causes Functional Thymulin Deficiency — And Zinc Supplementation Restores It. One Human Interventional Study from 1982. Extensive Animal Evidence. The Chapter That Is Also a Zinc Education.

NOT a Fragment of TA1 — the Full 28-Amino-Acid Thymosin Alpha-1 with an RGDR Tumor-Targeting Sequence Appended. The RGDR Motif Binds Integrin αvβ3 Overexpressed on Tumor Vasculature. A Chinese Pharmaceutical University Research Construct Designed to Concentrate TA1’s Immune Activation at Tumor Sites. What the Lao 2013 and Peng 2020 Papers Actually Show. The Community Use Question: Why a Cancer-Targeting Construct Is in General Use. What Companion Chapter pbta1v4 Covers vs What This Chapter Covers.